Explanipedia

Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial Open

Philipp Lurz, Rebecca T. Hahn, Susheel Kodali, Raj Makkar, Rahul Sharma , et al. · 2025

Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy v…

Outcomes of Tricuspid Transcatheter Edge-to-Edge Valve Repair in End-Stage Renal Disease Open

Lamiya T. Rodriguez, Keniel Pierre, JoAnn Lindenfeld, Rebecca R. Hung, Tarek Absi , et al. · 2025

Tricuspid Regurgitation and 3-Year Mortality After Transseptal Mitral Valve-in-Valve Replacement Open

Kashish Goel, JoAnn Lindenfeld, Pradeep Kumar Yadav, Rebecca T Hahn, Mayra Guerrero , et al. · 2025

Preprocedural severe or greater TR, 30-day residual severe or greater TR, and unchanged or worsened TR after transseptal MViV were associated with a significantly increased risk for 3-year all-cause mortality. These findings underscore the…

Real-World Clinical Outcomes and Health Care Utilization in Patients With Severe Tricuspid Regurgitation Open

Mahesh V. Madhavan, Colin M. Barker, Lisa K. Kemp, Sarah Mollenkopf, Michael P. Ryan , et al. · 2025

Over 3 years of follow-up, patients with severe TR had high rates of death and adverse clinical events and incurred substantial health care costs. Longer-term data regarding the impact of transcatheter interventions for severe TR on clinic…

Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States Open

Kashish Goel, Raj Makkar, Amar Krishnaswamy, Samir Kapadia, Susheel Kodali , et al. · 2024

BACKGROUND: Previous transcatheter valve therapy registry analyses of transcatheter mitral valve in valve (MViV) replacement of degenerated bioprosthesis reported early experience in the United States. Given recent increases in transseptal…

Invasive Assessment of Coronary Artery Disease in Clonal Hematopoiesis of Indeterminate Potential Open

J. Brett Heimlich, Michael A. Raddatz, John A. Wells, Caitlyn Vlasschaert, Sydney Olson , et al. · 2024

BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) occurs due to acquired mutations in bone marrow progenitor cells. CHIP confers a 2-fold risk of atherosclerotic cardiovascular disease. However, there are limited data rega…

D-25 | Cangrelor Use in Cardiogenic Shock - Findings from the CAMEO Registry Open

Cayla M. Pichan, Dennis I. Narcisse, Brooke Alhanti, Steven Kemp, Deepak L. Bhatt , et al. · 2024

Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y12 Inhibitor Therapy: The CAMEO Registry Open

Jennifer A. Rymer, Brooke Alhanti, Steven Kemp, Deepak L. Bhatt, Ajar Kochar , et al. · 2023

Bleeding risk was not observed to be significantly higher after cangrelor treatment in patients with and without upstream oral P2Y12 inhibitor exposure.

Backed Against a Wall: Iatrogenic Type A Aortic Dissection Pinned by Transcatheter Aortic Valve Open

Alexander E. Sullivan, Melissa M. Levack, Colin M. Barker, Kashish Goel · 2023

A 72-year-old female with severe symptomatic aortic stenosis was referred for aortic valve replacement. She was found to have a bicuspid aortic valve with left ventricular outflow tract calcification (Figure 1a and b) and an enlarged ascen…

Outcomes of transcatheter aortic valve replacement in patients with cardiogenic shock Open

Kashish Goel, Pinak Shah, Brandon Jones, Ethan C Korngold, Anju Bhardwaj , et al. · 2023

Aims The safety and efficacy of transcatheter aortic valve replacement (TAVR) with contemporary balloon expandable transcatheter valves in patients with cardiogenic shock (CS) remain largely unknown. In this study, the TAVRs performed for …

Ventricular Remodeling and Outcomes After Mitral Transcatheter Edge-to-Edge Repair in Heart Failure Open

Brian R. Lindman, Federico M. Asch, Paul Grayburn, Michael J. Mack, Jeroen J. Bax , et al. · 2023

PO-05-204 MULTI-CENTER CLINICAL OUTCOMES OF A NO-IMPLANT INTERATRIAL SHUNT FOR HEART FAILURE WITH PRESERVED AND REDUCED EJECTION FRACTION: UPDATE FROM THE EARLY FEASIBILITY ALLEVIATE-HF PROGRAM Open

Tamaz Shaburishvili, Gerard Wilkins, Benjamin J. Wilkins, Robert Gooley, S. Lockwood , et al. · 2023

D-33 | Transcatheter Edge-to-Edge Repair for Patients With Hypertrophic Cardiomyopathy and Severe Mitral Regurgitation Following Septal Myectomy Open

Bassim El‐Sabawi, Ashish S. Shah, D. Marshall Brinkley, Lynne W. Stevenson, Brian R. Lindman , et al. · 2023

Concomitant mitral valve surgery during septal myectomy for hypertrophic cardiomyopathy (HCM) is performed in <10% of patients and is associated with increased mortality. The objective of this study is to evaluate the feasibility, safety, …

E-42 | Multi-Center Clinical Outcomes of a No-Implant Interatrial Shunt for Heart Failure With Preserved and Reduced Ejection Fraction: Six-Month Outcomes from the ALLEVIATE-HF Feasibility Program Open

Molly Szerlip, Gerard Wilkins, Benjamin J. Wilkins, Robert Gooley, Siobahn Lockwood , et al. · 2023

Chronic heart failure (HFpEF and HFrEF) remains an important area of unmet need despite current best medical therapies available. Implantable interatrial shunt devices may improve quality of life and functional capacity with favorable safe…

Clonal Hematopoiesis of Indeterminate Potential Status is Associated with Left Main Artery Stenosis Open

J. Brett Heimlich, Michael A. Raddatz, John A. Wells, Caitlyn Vlasschaert, Sydney Olson , et al. · 2023

Clonal hematopoiesis of indeterminate potential (CHIP) occurs as a result of acquired mutations in bone marrow progenitor cells. CHIP confers a twofold risk of atherosclerotic cardiovascular disease (ASCVD). However, there is limited data …

Impact of Transcatheter Mitral Valve Repair Availability on Volume and Outcomes of Surgical Repair Open

Angela Lowenstern, Andrew M. Vekstein, Maria V. Grau‐Sepulveda, Vinay Badhwar, Vinod H. Thourani , et al. · 2023

Transcatheter Tricuspid Interventions: Past, Present, and Future Open

Colin M. Barker, Kashish Goel · 2023

Tricuspid regurgitation (TR) etiologies include primary valve pathology or secondary (functional) regurgitation from increased hemodynamic pressure or volume on the right side of the heart. Patients with severe TR have a worse prognosis in…

Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement Outcomes in Left Ventricular Assist Device Patients with Aortic Insufficiency Open

Aniket S. Rali, Siva Sagar Taduru, Lena Tran, Sagar Ranka, Kelly Schlendorf , et al. · 2022

Background: Worsening aortic insufficiency (AI) is a known sequela of prolonged continuous-flow left ventricular assist device (LVAD) support with a significant impact on patient outcomes. While medical treatment may relieve symptoms, it i…

Association of Transcatheter Aortic Valve Replacement Reimbursement, New Technology Add-on Payment, and Procedure Volumes With Embolic Protection Device Use Open

Angela Lowenstern, Anna Hung, Pratik Manandhar, Zachary K. Wegermann, Samir Kapadia , et al. · 2022

EPD use during TAVR remains infrequent and is associated with multiple patient and site characteristics. While CMS reimbursement varies significantly across institutions, TAVR case volume, rather than CMS TAVR reimbursement or the CMS new …

Feasibility of a No-Implant Approach to Interatrial Shunts: Preclinical and Early Clinical Studies Open

Colin M. Barker, Christopher Meduri, Peter Fail, Jeffrey W. Chambers, Darrell J. Solet , et al. · 2022

Combined, these data support the safety and feasibility of a novel no-implant approach to creating an interatrial shunt using the Alleviant System. Continued follow-up and subsequent clinical studies are currently ongoing.

LB-6 | No-implant Interatrial Shunt for Heart Failure: Multi-center Clinical Outcomes Open

Colin M. Barker, Gerard Wilkins, Benjamin J. Wilkins, Robert Gooley, Siobahn Lockwood , et al. · 2022

BackgroundHeart failure with preserved and reduced ejection fraction (HFpEF and HFrEF) remain major unmet clinical needs. Implantable interatrial shunt devices have shown favorable safety and efficacy signals but require permanent implanta…

Corrigendum to “Successful Orbital Atherectomy of Left Main Bifurcation Lesion Using Microcatheter Protection of Nonatherectomy Wire” Open

Alexander E. Sullivan, J. N. Shelton, Colin M. Barker, Kashish Goel · 2022

Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing Open

Oona Delpuech, Julie A. Douthwaite, Thomas Hill, Dhevahi Niranjan, Nancy T. Malintan , et al. · 2022

First in Man Use of a Leadless Pacemaker with the Evoque® Tricuspid Valve Open

George H. Crossley, Ansel P. Amaral, Travis D. Richardson, Colin M. Barker · 2022

There is an increasing recognition of the importance of tricuspid valve disease. Surgical treatment has been less than optimal and medical therapy has poor results. Catheter based delivery has revolutionized the delivery of aortic valve pr…

Successful Orbital Atherectomy of Left Main Bifurcation Lesion Using Microcatheter Protection of Nonatherectomy Wire Open

Alexander E. Sullivan, J. N. Shelton, Colin M. Barker, Kashish Goel · 2022

-Optimal PCI may be challenging with calcified left main bifurcation lesions-Orbital atherectomy is a common strategy for lesion optimization-Side branch occlusion is a feared complication of orbital atherectomy-Utilizing microcatheter wir…

Adjunctive Techniques for Repair of Ischaemic Mitral Regurgitation Open

Sigrid L Johannesen, Colin M. Barker, Melissa M. Levack · 2021

Ischaemic mitral regurgitation is a complex process with debate in the literature as to the optimal treatment pathway. Multiple therapies are available to alleviate mitral regurgitation including medical management, transcatheter edge-to-e…

Mortality and <span>guideline‐directed</span> medical therapy in <span>real‐world</span> heart failure patients with reduced ejection fraction Open

Peter A. McCullough, Hirsch Mehta, Colin M. Barker, Joanna Van Houten, Sarah Mollenkopf , et al. · 2021

Objective To estimate the prevalence of guideline‐directed medical therapy (GDMT) in commercially insured US patients with heart failure with reduced ejection fraction (HFrEF) and examine the effect of GDMT on all‐cause mortality. GDMT for…

Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction Open

Peter A. McCullough, Hirsch Mehta, Colin M. Barker, Joanna Van Houten, Sarah Mollenkopf , et al. · 2021

Aim: This study examines the effect of guideline-directed medical therapy (GDMT) on healthcare utilization in patients with heart failure with reduced ejection fraction from Optum ® Integrated File from 1 January 2007 to 30 June 2020. Mate…

Relation of Institutional Mitral Valve Surgical Volume to Surgical and Transcatheter Outcomes in Medicare Patients Open

Colin M. Barker, Matthew R. Reynolds, Michael J. Reardon, Joanna L. Van Houten, Shannon Murphy , et al. · 2021

There are limited data to support proposed increases to the minimum institutional mitral valve (MV) surgery volume required to begin a transcatheter mitral valve repair (TMVr) program. The current study examined the association between ins…

Healthcare utilization in clinically significant tricuspid regurgitation patients with and without heart failure Open

Colin M. Barker, David P. Cork, Peter A. McCullough, Hirsch Mehta, Joanna Van Houten , et al. · 2020

Aim: This study evaluated how the presence of right-sided heart disease (RSHD), other valve disease (OVD) and heart failure (HF) impacts healthcare utilization in patients with tricuspid valve disease (tricuspid regurgitation [TR]). Materi…

Colin M. Barker YOU? Author Swipe